4D Molecular Therapeutics expands portfolio with acquisition of eye disease asset.

4D Molecular Therapeutics has acquired the rights to the short-form human complement factor H (sCFH) asset from Aevitas Therapeutics, a subsidiary of Fortress Biotech. Meanwhile, Boehringer Ingelheim has inaugurated a new Germany-based research center, into which the company invested €350 million, to strengthen its biopharmaceuticals development. Additionally, Eli Lilly is planning to start testing its weight loss treatment candidate in a head-to-head clinical trial against Novo Nordisk’s Wegovy this month.